DAS Capital is a boutique investment advisory firm specializing in the life science sector with offices in Shanghai and Beijing, China. Unlike fully service investment banks, we primarily focus on three service lines Private Placement, M&A Strategy Development, and Mergers and Acquisitions Advisory.  Since our inception in 2019, DAS Capital has advised clients on more than US$2 billion worth of deals for medical devices, biopharma, tools & diagnostics, and digital health & health tech companies. We have worked on a range from early-stage financing of start-ups up to mergers and acquisitions for public companies. However, most of our clients are in their growth and expansion stages.  The team has extensive strategic consulting, investment, and industry experience. We position ourselves as the external “Strategic Business Development-SBD” team of growth-stage life science companies and leverage our expertise, industry insights, and network in the capital market and industry to support our clients’ growth. Our ECM team systematically covers over 4,000 local and overseas institutional investors, which include large Chinese conglomerates and industry heavyweights, public companies, financial institutions, government-backed funds, and family offices, as well as venture capital, private equity, mutual fund, and hedge fund players.